Sarepta Therapeutics
SRPT
#4401
Rank
โ‚น209.54 B
Marketcap
โ‚น2,000
Share price
-2.45%
Change (1 day)
-81.30%
Change (1 year)
Sarepta Therapeutics is an American medical research company dedicated to the discovery and development of precisely effective gene therapeutics for the treatment of rare neuromuscular diseases.

Revenue for Sarepta Therapeutics (SRPT)

Revenue in 2025 (TTM): โ‚น208.00 Billion

According to Sarepta Therapeutics 's latest financial reports the company's current revenue (TTM ) is โ‚น216.83 Billion. In 2024 the company made a revenue of โ‚น163.16 Billion an increase over the revenue in the year 2023 that were of โ‚น103.50 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Sarepta Therapeutics from 1997 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) โ‚น208.00 B27.48%
2024 โ‚น163.16 B57.64%
2023 โ‚น103.50 B34.06%
2022 โ‚น77.20 B47.79%
2021 โ‚น52.24 B32.26%
2020 โ‚น39.49 B45.45%
2019 โ‚น27.15 B29.02%
2018 โ‚น21.04 B113.26%
2017 โ‚น9.87 B2579.36%
2016 โ‚น0.36 B342.41%
2015 โ‚น83.26 M-86.53%
2014 โ‚น0.61 B-29.61%
2013 โ‚น0.87 B-57.02%
2012 โ‚น2.04 B-17.78%
2011 โ‚น2.48 B88.55%
2010 โ‚น1.31 B61.54%
2009 โ‚น0.81 B-20.13%
2008 โ‚น1.02 B137.01%
2007 โ‚น0.43 B8342.88%
2006 โ‚น5.1 M-97.63%
2005 โ‚น0.21 B1054.73%
2004 โ‚น18.64 M-57.78%
2003 โ‚น44.15 M10.04%
2002 โ‚น40.12 M17.78%
2001 โ‚น34.07 M-43.73%
2000 โ‚น60.54 M596.4%
1999 โ‚น8.69 M-48.88%
1998 โ‚น17 M44.26%
1997 โ‚น11.78 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Gilead Sciences
GILD
โ‚น2.612 T 1,105.03%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
โ‚น92.02 B-57.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Avidity Biosciences
RNA
โ‚น1.87 B-99.14%๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
โ‚น53.88 B-75.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
โ‚น288.38 B 32.99%๐Ÿ‡บ๐Ÿ‡ธ USA
PTC Therapeutics
PTCT
โ‚น159.83 B-26.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Insmed
INSM
โ‚น40.15 B-81.48%๐Ÿ‡บ๐Ÿ‡ธ USA